Carnosic acid protects SH-SY5Y cells against 6-hydroxydopamine-induced cell death through upregulation of parkin pathway.
Parkin is a Parkinson's disease (PD)-linked gene that plays an important role in the ubiquitin-proteasome system (UPS). This study explored whether carnosic acid (CA) from rosemary protects against 6-hydroxydopamine (6-OHDA)-induced neurotoxicity via upregulation of parkin in vivo and in vitro. We found that the reduction in proteasomal activity by 6-OHDA was attenuated in SH-SY5Y cells pretreated with 1 μM CA. Immunoblots showed that CA reversed the induction of ubiquitinated protein and the reduction of PTEN-induced putative kinase 1 (PINK1) and parkin protein in 6-OHDA-treated SH-SY5Y cells and rats. Moreover, in a transgenic OW13 Caenorhabditis elegans model of PD that expresses human α-synuclein in muscle cells, CA reduced α-synuclein accumulation in a dose-dependent manner. In cells pretreated with the proteasome inhibitor MG132, CA no longer reversed the 6-OHDA-mediated induction of cleavage of caspase 3 and poly(ADP)-ribose polymerase and no longer reversed the suppression of proteasome activity. When parkin expression was silenced by use of small interfering RNA, the ability of CA to inhibit apoptosis and induce proteasomal activity was significantly reduced. The reduction in 6-OHDA-induced neurotoxicity by CA was associated with the induction of parkin, which in turn upregulated the UPS and then decreased cell death.
Department of Nutrition, China Medical University, Taichung, Taiwan.
Chia-Yuan
CY
Lin
Department of Nutrition, China Medical University, Taichung, Taiwan.
Chia-Wen
CW
Tsai
Department of Nutrition, China Medical University, Taichung, Taiwan. Electronic address: cwtsai@mail.cmu.edu.tw.
Chia-Wen
CW
Tsai
D045784:Abietanes / Q000494:pharmacology*; D000818:Animals; D030801:Animals, Genetically Modified; D000975:Antioxidants / Q000494:pharmacology; D017173:Caenorhabditis elegans; D016923:Cell Death / Q000187:drug effects / Q000502:physiology; D045744:Cell Line, Tumor; D019610:Cytoprotection / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D008297:Male; D016627:Oxidopamine / Q000633:toxicity*; D051381:Rats; D017208:Rats, Wistar; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology; D044767:Ubiquitin-Protein Ligases / Q000096:biosynthesis*; D015854:Up-Regulation / Q000187:drug effects / Q000502:physiology*; D051844:alpha-Synuclein / Q000096:biosynthesis
D045784:Abietanes; D000975:Antioxidants; D051844:alpha-Synuclein; D016627:Oxidopamine; D044767:Ubiquitin-Protein Ligases; C111567:parkin protein; C018381:salvin
6-Hydroxydopamine hydrobromide (PubChem CID: 176170); Carnosic acid; Carnosic acid (PubChem CID: 65126); Dimethyl sulfoxide (PubChem CID: 679); MG132 (PubChem CID: 462382); Neuroprotection; Parkin; Penicillin Streptomycin (PubChem CID: 86591708); Triton X-100 (PubChem CID: 5590); Tween 20 (PubChem CID: 443314); Ubiquitin-proteasomal system; α-synuclein